BJDX

Bluejay Diagnostics, Inc. NASDAQ Listed Nov 10, 2021

Healthcare ·Medical - Devices ·US · bluejaydx.com

$1.82

Mkt Cap $825,445

52w Low $1.65 1.1% of range 52w High $16.68

50d MA $1.93 200d MA $4.57

P/E (TTM) -0.1x

EV/EBITDA 0.6x

P/B 0.1x

Debt/Equity 0.0x

ROE -114.6%

P/FCF -0.2x

RSI (14) —

ATR (14) —

Beta 0.67

50d MA $1.93

200d MA $4.57

Avg Volume 218.9K

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

SIC Code

3841

CIK (SEC)

1704287

Phone

844 327 7078

360 Massachusetts Avenue · Acton, MA 01720 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 6, 2026	AMC	—	-2.37	—	1.86	-0.5%	+0.5%	+2.7%	+5.7%	-2.5%	-4.0%	—
Nov 7, 2025	AMC	—	-4.04	—	6.28	-0.6%	+0.0%	+10.2%	-6.4%	-4.3%	-4.5%	—
Aug 7, 2025	AMC	—	-1.41	—	5.88	-0.7%	-4.8%	+34.3%	-21.3%	-6.8%	-5.1%	—
May 13, 2025	AMC	—	-3.37	—	7.24	-3.9%	-5.5%	+4.1%	+0.6%	+7.8%	-1.0%	—
Mar 31, 2025	AMC	-144.00	-112.37	+22.0%	14.92	-0.3%	-2.9%	+2.2%	-12.2%	+8.6%	+112.5%	—
Nov 7, 2024	AMC	-144.00	-8.00	+94.4%	18.52	-13.6%	-1.7%	+3.5%	+14.6%	-3.7%	-28.8%	—
Aug 14, 2024	AMC	-144.00	-256.00	-77.8%	59.56	-1.9%	+2.8%	-12.4%	+12.2%	-4.9%	-10.8%	—
May 15, 2024	AMC	-1152.00	-396.00	+65.6%	840.00	+6.4%	+9.5%	+0.9%	-6.8%	-5.6%	-3.0%	—
Mar 28, 2024	AMC	-272.00	-712.00	-161.8%	1284.48	-1.3%	-4.0%	-1.9%	-4.8%	-1.7%	-6.7%	—
Nov 9, 2023	AMC	-328.00	-832.00	-153.7%	5040.00	+0.8%	+5.7%	+1.8%	-2.7%	+3.0%	-2.1%	—
Aug 14, 2023	AMC	-600.00	-1100.00	-83.3%	12368.00	+12.4%	-2.2%	+0.9%	-1.2%	-3.6%	+2.8%	—
May 10, 2023	AMC	-480.00	-960.00	-100.0%	9283.20	+6.9%	+3.4%	-6.7%	+0.0%	-1.5%	+15.3%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Aug 3	Dawson James	Downgrade	Buy → Neutral	—	$8736.00	$16800.00	+92.3%	+52.2%	-4.2%	+2.9%	+7.7%	-5.9%
Jan 12	Dawson James	Maintains	Buy → Buy	—	$87680.00	$101440.00	+15.7%	+0.0%	-2.9%	+0.0%	-3.2%	-4.5%

Data updated apr 24, 2026 9:46pm · Source: massive.com